Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis
April 16th 2019The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.
Pascal Sati, PhD: Challenges in Imaging for Multiple Sclerosis
April 8th 2019The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke gave a presentation on a volumetric segmented echo-planar-imaging (3D-EPI) sequence, which could be used to detect novel biomarkers such as the central vein sign rapidly.
Rhonda Voskuhl, MD: A Bedside to Bench to Bedside Approach in MS
April 2nd 2019The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program stressed the importance of basing research on clinical observations, understanding them in the lab, then designing novel clincal trials.
John DeLuca, PhD: Ozanimod Resulted in Improved Cognitive Processing Speed in Relapsing MS
March 30th 2019The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.
Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS
March 28th 2019The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.
David Leppert, MD: Building a Foundation for Neurofilament Light
March 22nd 2019The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.